Skip to main content
. 2022 Oct 21;13:965770. doi: 10.3389/fphar.2022.965770

TABLE 2.

Comparison of the clinical efficacy between the two groups.

Group Complete response Partial response Stable disease Disease progression Objective response rate
TACE-LEN (n = 53) 12 (22.64%) 29 (54.72%) 9 (16.98%) 3 (5.66%) 41 (77.36%)
TACE (n = 51) 6 (11.76%) 23 (45.10%) 12 (23.53%) 10 (19.61%) 29 (56.86%)
χ 2 4.962
P 0.026